CONTEXT: Diabetes is associated with the reduction of beta cell mass and activity. Cholecystokinin (CCK) is known to induce growth of the exocrine pancreas and to stimulate insulin secretion. OBJECTIVE: We investigated the possible role of CCK-octapeptide (CCK-8) in generating islet cell proliferation in type 1 and type 2 diabetic rats. METHODS: Streptozotocin-induced type 1 diabetic rats, streptozotocin/nicotinamide-induced type 2 diabetic rats and non-diabetic rats were subjected to CCK-8 (1, 2 and 4 microg/kg) or saline injections (for the control group), three times daily for 8 successive days. MAIN OUTCOME MEASURES: The islets of Langerhans were analyzed morphometrically; the beta-cell function was evaluated by an oral glucose tolerance test, and plasma basal glucose and insulin concentrations. RESULTS: In type 1 diabetic rats, CCK-8 induced an increase in beta cell surface associated with a marked increase in the mitotic index; this effect appeared at a concentration of 1 microg/kg CCK-8 and was the highest at a concentration of 4 microg/kg CCK-8. In addition, pancreatic- and plasma-insulin concentrations increased while fasting blood glucose concentrations were reduced when compared to saline-treated rats but the glycemic response to an oral glucose challenge did not significantly improve. In type 2 diabetic rats and in non-diabetic rats, CCK-8 treatment did not significantly affect either the structure or the functional state of beta-cells. CONCLUSIONS: CCK-8 could improve blood glucose concentrations in type 1 diabetic rats correlated with an increase in beta cell mass probably potentiated by the chronic hyperglycemic state.
CONTEXT: Diabetes is associated with the reduction of beta cell mass and activity. Cholecystokinin (CCK) is known to induce growth of the exocrine pancreas and to stimulate insulin secretion. OBJECTIVE: We investigated the possible role of CCK-octapeptide (CCK-8) in generating islet cell proliferation in type 1 and type 2 diabeticrats. METHODS:Streptozotocin-induced type 1 diabeticrats, streptozotocin/nicotinamide-induced type 2 diabeticrats and non-diabeticrats were subjected to CCK-8 (1, 2 and 4 microg/kg) or saline injections (for the control group), three times daily for 8 successive days. MAIN OUTCOME MEASURES: The islets of Langerhans were analyzed morphometrically; the beta-cell function was evaluated by an oral glucose tolerance test, and plasma basal glucose and insulin concentrations. RESULTS: In type 1 diabeticrats, CCK-8 induced an increase in beta cell surface associated with a marked increase in the mitotic index; this effect appeared at a concentration of 1 microg/kg CCK-8 and was the highest at a concentration of 4 microg/kg CCK-8. In addition, pancreatic- and plasma-insulin concentrations increased while fasting blood glucose concentrations were reduced when compared to saline-treated rats but the glycemic response to an oral glucose challenge did not significantly improve. In type 2 diabeticrats and in non-diabeticrats, CCK-8 treatment did not significantly affect either the structure or the functional state of beta-cells. CONCLUSIONS:CCK-8 could improve blood glucose concentrations in type 1 diabeticrats correlated with an increase in beta cell mass probably potentiated by the chronic hyperglycemic state.
Authors: Jeremy A Lavine; Philipp W Raess; Donald S Stapleton; Mary E Rabaglia; Joshua I Suhonen; Kathryn L Schueler; James E Koltes; John A Dawson; Brian S Yandell; Linda C Samuelson; Margery C Beinfeld; Dawn Belt Davis; Marc K Hellerstein; Mark P Keller; Alan D Attie Journal: Endocrinology Date: 2010-06-09 Impact factor: 4.736
Authors: Jeremy A Lavine; Carly R Kibbe; Mieke Baan; Sirinart Sirinvaravong; Heidi M Umhoefer; Kimberly A Engler; Louise M Meske; Kaitlyn A Sacotte; Daniel P Erhardt; Dawn Belt Davis Journal: Am J Physiol Endocrinol Metab Date: 2015-09-22 Impact factor: 4.310
Authors: Michelle Kim; Perri Deacon; Rommel G Tirona; Richard B Kim; Christopher L Pin; Henriette E Meyer Zu Schwabedissen; Rennian Wang; Ute I Schwarz Journal: Histochem Cell Biol Date: 2017-05-10 Impact factor: 4.304
Authors: Jeremy A Lavine; Philipp W Raess; Dawn Belt Davis; Mary E Rabaglia; Brent K Presley; Mark P Keller; Margery C Beinfeld; Alan S Kopin; Christopher B Newgard; Alan D Attie Journal: Mol Endocrinol Date: 2008-10-09